CN1513539A - Preparation technology of supplementing kind capsule - Google Patents
Preparation technology of supplementing kind capsule Download PDFInfo
- Publication number
- CN1513539A CN1513539A CNA2003101192231A CN200310119223A CN1513539A CN 1513539 A CN1513539 A CN 1513539A CN A2003101192231 A CNA2003101192231 A CN A2003101192231A CN 200310119223 A CN200310119223 A CN 200310119223A CN 1513539 A CN1513539 A CN 1513539A
- Authority
- CN
- China
- Prior art keywords
- treatment
- examples
- preparation technology
- group
- supplementing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000005516 engineering process Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 title claims description 3
- 239000002775 capsule Substances 0.000 title abstract description 6
- 230000001502 supplementing effect Effects 0.000 title 1
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000001959 radiotherapy Methods 0.000 abstract description 2
- 230000001256 tonic effect Effects 0.000 abstract 2
- 241000735234 Ligustrum Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000036528 appetite Effects 0.000 description 5
- 235000019789 appetite Nutrition 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000010354 integration Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 2
- 230000004596 appetite loss Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000019017 loss of appetite Diseases 0.000 description 2
- 235000021266 loss of appetite Nutrition 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A tonic capsule for the weak patient and the patient after operating, radiotherapy or chemicotherapy is prepared from lucid ligustrum fruit and astragalus root through decocting three times, collecting decoction, ultrafiltering, concentrating, granulating, drying and loading in capsules. Its advantages are high tonic effect and low dosage.
Description
Technical field:
The present invention relates to a kind ofly prepare capsular technology with Chinese herbal medicine.
Technical background:
It generally all is to filter with 200 eye mesh screens that traditional tonification class Chinese herbal medicine prepares in the capsule technology filter method, can not remove macromole impurity such as colloid in the medicinal liquid, tannin, protein, causes drug effect not good, and dose is big, and draws moist strong.
Summary of the invention:
The objective of the invention is to: provide a kind of method with ultrafiltration to produce the Chinese herbal medicine capsule, it can play separation, purification, spissated effect, to improve drug effect, reduces dose.
The present invention is achieved in that getting Fructus Ligustri Lucidi, the Radix Astragali extracts 3 times, and merge extractive liquid, carries out ultrafiltration again, and filtrate is concentrated into the clear paste of relative density 1.07～1.09, makes granule after the drying, and is dry, promptly encapsulated again.
The present invention compared with prior art, it is effective to have a tonification, advantage such as dose is few, and drug effect is good.Its dose can be more traditional medicine reduce 1/3.It is deficient to be used for prolonged illness, deficiency of both vital energy and Yin; Cooperate operation, radiotherapy, chemotherapy, promote the recovery of normal function.Concrete clinical trial brief summary is as follows:
1 materials and methods
1.1 physical data: inpatient 132 examples in whole cases, out-patient's 18 examples; In observation group's ratio, male 52 examples, women 48 examples, matched group man 27 examples, women 23 examples; Age is between 38～69 years old.The malignant tumor case is all clarified a diagnosis, and estimates life cycle more than 3 months, and Ka Shi divides equally 〉=and 60 minutes, sick kind situation sees Table 1.
Table a kind of distribution
Hundreds of minutes rates (%) of the tumor example chronic case of number percentage rate (%)
Pulmonary carcinoma 36 41.4 diabetes 18 28.5
Hepatocarcinoma 6 6.8 liver cirrhosis 16 25.4
Woman's cancer 24 27.4 atrophic gastritis 14 22.3
Nasopharyngeal carcinoma 12 13.8 chronic bronchitis scorching 8 12.7
Dislike and drench 4 4.6 chronic colitiss 4 6.3
Breast carcinoma 7 8.0 other 3 4.8
Subtotal 87 100 63 100
1.2 method
150 routine patients adopt and singly educate the method random packet, 100 5 of the present invention of example of observation group, and 3 times on the 1st are oral, the matched group lentinan film, 5,3 times on the 1st are oral, 6 weeks of the course of treatment.Inactive other related drugs in the observation process, but chemicotherapy is proceeded.
1.3 observation index
1.3.1 clinical disease scoring, according to tcm symptom classification person scoring, each record once before and after the treatment.
Table 2 tcm symptom hierarchical table
Symptom 0 minute 1 minute 2 minutes 3 minutes 4 minutes
It is tired that Mental fatigue does not have slightly sense, can hard fatiguability, can not hard fatiguability, and need others to be fagged out, need medical treatment
The work of holding is held work and is helped nursing
Vomiting and nausea does not have idol and has and feel sick to feel sick obviously, and 3～5 vomitings of vomiting feed vomiting are more than 5 times/d,
The difficult control of 1-2 time/day/d
Indigestion and loss of appetite no poor appetite, appetite appetite reduce appetite more at ordinary times and reduce appetite more at ordinary times and reduce more at ordinary times
Do not subtract more than 1/3 1/2 2/3
Heating does not have＜38 ℃,＜2d＜38 ℃, and＞2d, 38 °～40 ℃, more than＞40 ℃,＞2d,
Or 38 °～40 ℃, 2d or more than 40 ℃, or 38 °～40 ℃ held
Continuous 1 week of＜2d＜1d or＜38 ℃
Continue January
Tcm symptom efficacy assessment standard: clinical treatment: all transference cures of treatment back, symptom integral reduces to 0; Produce effects: symptom is most to disappear, and integration reduces more than 2/3 before the integration ratio treatment of treatment back; Effectively: symptom takes a turn for the better, and integration reduces more than 1/3, and invalid: symptom does not have obvious improvement, integration with treat before equate or reduction less than 1/3.
1.3.2 peripheral blood WBC and Hb criterion of therapeutical effect: produce effects: WBC, Hb treatment back rises 1.0 * 10 respectively before treating
9/ L, 30g/L, effectively: WBC and Hb rising less than 1.0 * 10
9/ L, 30g/L, or maintain 4.0 * 10
9/ L, more than the 90g/L; Invalid: as to treat back WBC and Hb no change or reduce to 4.0 * 10 respectively
9/ L and below the 90g/L.
1.3.3 improve the immune indexes criterion of therapeutical effect: learn processing by statistics with immune indexes measured value average before and after the administration and judge.
1.3.4 life quality scoring: with the Ka Shi standards of grading, score respectively before and after treating, the score raising should be raising in 10 minutes before and after the treatment, reduced 10 fens and should be reduction, increased or reduce less than 10 minutes should be stable.
2 results
2.1 clinical symptoms curative effect: observation group's 100 examples, produce effects 80 examples (80%), effective 14 examples (14%), invalid 6 examples (6%), total effective rate 94%, matched group 50 examples, produce effects 10 examples (20%), effective 20 examples (40%), invalid 20 examples (40%), total effective rate 60%.
Results suggest: comparing difference for two groups has highly significant, P＜0.01.
2.2 the rising effect of peripheral blood WBC and Hb sees Table 3
Table 3 peripheral blood WBC and Hb rising effect
Index group example digital display is imitated (%) effectively (%) invalid (%) total effective rate %
WBC observation group 80 54 (67.5) 22 (27.5) 4 (5) 95.0
Matched group 42 8 (19.00) 12 (28.6) 22 (52.4) 47.6
P＜0.01
Hb observation group 80 65 (81.2) 7 (8.8) 8 (10) 90
Matched group 42 5 (11.9) 20 (47.6) 17 (40.5) 59.5
P＜0.01
Results suggest: observation group compares statistical analysis with matched group have highly significant difference (P＜0.01=.
2.3 immune indexes t lymphocyte subset group's variation before and after the treatment is carried out statistical procedures with the average of two groups of Tumor Patient Before and After Treatment TH, TS, TH/TS in 6 weeks, the results are shown in Table 4.
Tumor Patient Before and After Treatment T lymphocyte variation in the table 4 liang group (X ± S)
| Group | The example number | ??????????????T H(％) | ?????????????T S(％) | ???????????????T H/T S(％) | ||||||
| Observation group's matched group | ??60 ??27 | Before the treatment | After the treatment | P | Before the treatment | After the treatment | P | Before the treatment | After the treatment | ??P |
| 34.8± 6.2 35.9± 7.6 | 41.2± 7.1 37.0± 6.9 | ＜ 0.01 ＞ 0.05 | 41.6± 5.1 39.9± 7.4 | 33.8± 7.6 40.1± 6.6 | ＜ 0.01 ＞ 0.05 | 0.91± 0.32 0.98± 0.49 | 0.96± 0.40 0.97± 0.44 | ＜ 0.01 ＞ 0.05 | ||
Last table result shows, the T of observation group
HAnd T
H/ T
SRatio rises obviously (P＜0.01), T
SDescend obviously, no significant change (P＞0.05) before and after the treatment of control group illustrates that the present invention has the curative effect that improves cellular immune function.
2.4 quality of life is estimated, and sees Table 5
Table 5 observation group
Quality of life changes before and after the 100 example treatments
Effect
Example number ratio (%)
Improve 42 42
Stablize 39 39
Reduce by 55
Invalid 14 14
3 conclusions
The present invention is the presentation of results after 6 weeks to 100 routine malignant tumor and chronic deficient property disease patient treatment: this medicine can significantly improve patient's spiritlessness and weakness, vomiting and nausea, heating, symptom such as indigestion and loss of appetite, improve the measured value of patient's peripheral blood WBC, Hb, significantly increase cell immune function of human body, quality of life is significantly improved, the effect of its strengthening the body resistance obtains embodying in many-side, the active drug of can yet be regarded as treatment malignant tumor and other deficient property chronic disease.
The specific embodiment:
Embodiments of the invention: to produce 1000 is example, gets Fructus Ligustri Lucidi 467g, and Radix Astragali 933g pulverizes, decoct with water 3 times (the 1st 10 times of water gagings, the 2nd, 3 time add 8 times of water gagings respectively) the 1st time 2 hours, 2nd, 3 times each 1 hour, collecting decoction filters with 200 eye mesh screens, and the reuse molecular weight that dams is that 50000 hollow fiber ultrafiltration membrane is carried out ultrafiltration, filtrate is concentrated into the clear paste of relative density 1.07～1.09 (50 ℃), make granule after the drying, dry again, adorn 1000 capsules promptly.
Claims (1)
1, the capsular preparation technology of a kind of tonification class is characterized in that: get Fructus Ligustri Lucidi, Radix Astragali extraction 3 times, merge extractive liquid, carries out ultrafiltration again, and filtrate is concentrated into the clear paste of relative density 1.07～1.09, makes granule after the drying, and is dry, promptly encapsulated again.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200310119223 CN1284548C (en) | 2003-04-01 | 2003-11-20 | Preparation technology of supplementing kind capsule |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03117610.0 | 2003-04-01 | ||
| CN 03117610 CN1454642A (en) | 2003-04-01 | 2003-04-01 | Tonifying capsule preparing process |
| CN 200310119223 CN1284548C (en) | 2003-04-01 | 2003-11-20 | Preparation technology of supplementing kind capsule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513539A true CN1513539A (en) | 2004-07-21 |
| CN1284548C CN1284548C (en) | 2006-11-15 |
Family
ID=34276257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200310119223 Expired - Fee Related CN1284548C (en) | 2003-04-01 | 2003-11-20 | Preparation technology of supplementing kind capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1284548C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101805413A (en) * | 2010-04-01 | 2010-08-18 | 苏州宝泽堂医药科技有限公司 | Preparation method of ligustrum lucidum polysaccharide |
| CN105267308A (en) * | 2014-06-27 | 2016-01-27 | 北京海吉星医疗科技有限公司 | Traditional Chinese medicine combination having anti-tumor activity |
| CN105311116A (en) * | 2014-06-27 | 2016-02-10 | 北京海吉星医疗科技有限公司 | Medicine composition for treating asthenic disease |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1518924B8 (en) * | 2002-06-25 | 2007-11-21 | Sapporo Breweries Limited | Beer-like alcoholic beverage and process for producing the same |
-
2003
- 2003-11-20 CN CN 200310119223 patent/CN1284548C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101805413A (en) * | 2010-04-01 | 2010-08-18 | 苏州宝泽堂医药科技有限公司 | Preparation method of ligustrum lucidum polysaccharide |
| CN105267308A (en) * | 2014-06-27 | 2016-01-27 | 北京海吉星医疗科技有限公司 | Traditional Chinese medicine combination having anti-tumor activity |
| CN105311116A (en) * | 2014-06-27 | 2016-02-10 | 北京海吉星医疗科技有限公司 | Medicine composition for treating asthenic disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1284548C (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1739695A (en) | Chinese medicine for treating cataract and its prepn | |
| CN1895547A (en) | Medicine for treating diabetes and its preparation | |
| CN1233389C (en) | Chinese materia medica preparation made from gen-seng and astragalus root for strengthening the body resistance and anti cancer as well as producing method | |
| CN1055638C (en) | Selenium-riched Chinese caterpillar fungus oral liquor and its prepn. method | |
| CN1899448A (en) | Chinese medicine compound preparation for treating amblyopia and its preparing method | |
| CN1513539A (en) | Preparation technology of supplementing kind capsule | |
| CN1895593A (en) | Medicine for treating acne and its preparation | |
| CN1285367C (en) | Medicinal preparation for treating diabetes and its preparation method | |
| CN101543612B (en) | Chinese medicament for treating malignant lymphoma | |
| CN1041494C (en) | Chinese-medicinal powder and capsule for treating chronic ischemic heart disease | |
| CN1836702A (en) | Medicine for treating tumour and its preparing method | |
| CN1255146C (en) | Medicine composition for treating uppe respiration channel infetion and its preparing process | |
| CN1899385A (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN1383867A (en) | Medicine for treating depression and its prepn | |
| CN1101559A (en) | Traditional Chinese medicine oral administration liquid for anti-cancer and its preparing method | |
| CN100340232C (en) | Jinshu leaf styptic mixture and its preparing method and use | |
| CN101062292A (en) | Medicine for treating cancer and preventing lung cancer and preparing method thereof | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process | |
| CN1094062C (en) | Chiense medicine for treating hepatitis B together with aweto-cephalosporin mycelium and its preparation | |
| CN1140281C (en) | Yiyuansan powder as one orally taken medicine for treating liver cancer and its preparation | |
| CN1634541A (en) | Medicine for treating fatigue syndrome and preventing presenility, and preparation method thereof | |
| CN1943717A (en) | A Chinese traditional medicinal composition for treatment of low blood pressure and its preparation method | |
| CN1768778A (en) | Application of cassia seed in preparation of lead-remove promoting drug or health-caring product | |
| CN1256083C (en) | Medicine for boosting qi and nourishing blood and its prepatation method | |
| CN1064249C (en) | Traditional Chinese medicine for indication nearsight |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Effective date of registration: 20080424 Pledge (preservation): Pledge |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20110930 Granted publication date: 20061115 Pledgee: Agricultural Bank of China branch of Luodian County Pledgor: GUIZHOU XINBANG PHARMACEUTICAL Co.,Ltd.|XINBANG YUANDONG PHARMACEUTICA Registration number: 2008520000426 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation technology of supplementing kind capsule Effective date of registration: 20110930 Granted publication date: 20061115 Pledgee: Agricultural Bank of China Limited by Share Ltd. Luodian branch Pledgor: GUIZHOU XINBANG PHARMACEUTICAL Co.,Ltd.|XINBANG YUANDONG PHARMACEUTICA Registration number: 2011990000379 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170420 Granted publication date: 20061115 Pledgee: Agricultural Bank of China Limited by Share Ltd. Luodian branch Pledgor: GUIZHOU XINBANG PHARMACEUTICAL Co.,Ltd.|XINBANG YUANDONG PHARMACEUTICA Registration number: 2011990000379 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation technology of supplementing kind capsule Effective date of registration: 20170517 Granted publication date: 20061115 Pledgee: Agricultural Bank of China Limited by Share Ltd. Luodian branch Pledgor: GUIZHOU XINBANG PHARMACEUTICAL Co.,Ltd.|XINBANG YUANDONG PHARMACEUTICA Registration number: 2017520000004 |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181214 Address after: 550018 6th Floor, Kekaiyuan, Koujie Road Estuary, Wudang District, Guiyang City, Guizhou Province Patentee after: GUIZHOU XINBANG PHARMACEUTICAL Co.,Ltd. Address before: 550003 No. 75 Ruijin North Road, Guiyang City, Guizhou Province Patentee before: XINBANG YUANDONG PHARMACEUTICA |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210420 Granted publication date: 20061115 Pledgee: Agricultural Bank of China Limited by Share Ltd. Luodian branch Pledgor: GUIZHOU XINBANG PHARMACEUTICAL Co.,Ltd. Registration number: 2017520000004 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061115 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |